U.S. Telecom Services and Carriers Stock News

NasdaqGS:HTLD
NasdaqGS:HTLDTransportation

Heartland Express (HTLD) Trailing Losses Of US$52.5 Million Test Bullish Profitability Narratives

Heartland Express (HTLD) opened 2026 with Q1 results that extend a run of soft profitability, capped by trailing 12 month revenue of US$805.7 million and a basic EPS loss of US$0.67 tied to a net loss of US$52.5 million. Over the past six reported quarters, quarterly revenue has ranged from US$179.4 million to US$259.9 million, while basic EPS has moved between a loss of US$0.02 and a loss of US$0.25. This sets up a story where investors are weighing ongoing losses against forecasts that...
NasdaqGS:SHOP
NasdaqGS:SHOPIT

A Look At Shopify (SHOP) Valuation As Q1 Growth Expectations And AI Tools Draw Fresh Attention

Shopify (SHOP) is back in focus as fresh commentary around its upcoming Q1 report highlights solid gross merchandise value trends, merchant growth, and heavier use of its tools, drawing renewed attention to the stock’s recent pullback. See our latest analysis for Shopify. At a share price of $124.23, Shopify has seen a 1-day share price return of 5.86% decline and a year to date share price return of 20.97% decline. However, the 1-year total shareholder return of 30.60% and 3-year total...
NasdaqGS:MMLP
NasdaqGS:MMLPOil and Gas

Martin Midstream Partners (MMLP) Losses Challenge Bullish Valuation Narrative Ahead Of Q1 2026 Earnings

Martin Midstream Partners (MMLP) opened 2026 with Q1 results that keep the focus squarely on profitability, as the latest trailing 12 month figures show total revenue of US$716.1 million and a loss of US$14.4 million, or basic EPS of US$0.37. Over recent quarters, the partnership has seen quarterly revenue range from US$168.7 million to US$192.5 million, while basic EPS has moved between a profit of US$0.09 and losses of up to US$0.21. This sets up an earnings release where investors are...
NasdaqGM:RZLV
NasdaqGM:RZLVSoftware

Rezolve AI (RZLV) Valuation Check After Microsoft Foundry Commerce AI Partnership

Rezolve AI (RZLV) drew fresh attention after announcing its brainpowa commerce-tuned AI model suite is now available within Microsoft Foundry, giving brands access to commerce-focused copilots deployed directly on Microsoft Azure. See our latest analysis for Rezolve AI. Despite the Microsoft Foundry news and a last close of $2.60, Rezolve AI’s recent momentum has been mixed, with a 1-month share price return of 1.17% but a 90-day share price decline of 17.20%, alongside a 1-year total...
NasdaqGM:LSBK
NasdaqGM:LSBKBanks

Lake Shore Bancorp (LSBK) Net Profit Margin Improvement Challenges Cautious Earnings Narratives

Lake Shore Bancorp (LSBK) has just wrapped up Q4 2025 with total revenue of US$7.3 million, basic EPS of US$0.26 and net income of US$1.9 million, while trailing twelve month figures show revenue of US$28.0 million and EPS of US$0.97, alongside 47.4% earnings growth over the past year. Over recent quarters, the company has seen revenue move from US$6.4 million and EPS of US$0.17 in Q3 2024 to US$7.7 million and EPS of US$0.32 in Q3 2025, before settling at Q4 2025 levels. This progression...
NYSE:OBK
NYSE:OBKBanks

Origin Bancorp (OBK) Net Margin Improvement Tests Bullish Growth Narratives In Q1 2026 Results

Origin Bancorp (OBK) has just posted Q1 2026 results with revenue of US$99.1 million and Basic EPS of US$0.89, setting the tone for how the year is starting after a run of solid quarterly contributions to trailing 12 month EPS of US$2.60 and net income of US$80.5 million. Over recent quarters, revenue has moved from US$83.4 million in Q4 2024 to US$90.6 million in Q1 2025 and US$99.8 million in Q4 2025. Quarterly Basic EPS has ranged from US$0.46 to US$0.95 across that same stretch, giving a...
NasdaqGS:INBX
NasdaqGS:INBXBiotechs

Why Inhibrx Biosciences (INBX) Is Up 44.3% After Ozekibart Colorectal Cancer Efficacy Update And What's Next

Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma. These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

Popular (BPOP) Net Margin Expansion Reinforces Bullish Efficiency Narrative Ahead Of Q1 2026

Popular (BPOP) has just posted another solid quarter, with Q4 2025 revenue of US$751.8 million and basic EPS of US$3.54, setting the tone as investors look at the new Q1 2026 reporting period. The bank has seen quarterly revenue move from US$689.4 million in Q4 2024 to US$751.8 million in Q4 2025, while basic EPS over that same stretch climbed from US$2.51 to US$3.54, giving you a clear sense of how the income line has scaled alongside the top line. Taken together with an improved net profit...
OTCPK:KTHN
OTCPK:KTHNBanks

Katahdin Bankshares (OTCPK:KTHN) Margin Improvement Challenges Long Term Earnings Slowdown Narrative

Katahdin Bankshares (KTHN) has just put another quarter on the board, with Q4 2025 revenue of US$11.9 million and basic EPS of US$0.99 setting the tone after a year in which trailing net income reached US$10.7 million on revenue of US$44.3 million. Over recent periods the company has seen revenue move from US$9.5 million and EPS of roughly US$0.56 in Q4 2024 to US$11.9 million and US$0.99 respectively in Q4 2025. Trailing basic EPS for the last reported twelve months reached about US$3.37...
OTCPK:ARBV
OTCPK:ARBVBanks

American Riviera Bancorp (OTCPK:ARBV) Net Profit Margin Improvement Challenges Bearish Earnings Narrative

American Riviera Bancorp (ARBV) opened 2026 with Q1 results that build on a solid finish to last year, with Q4 2025 revenue at about US$14.4 million and basic EPS of roughly US$0.80, while trailing twelve month revenue stood at about US$50.4 million and EPS at roughly US$2.18. Over recent quarters, revenue has moved from about US$10.7 million in Q4 2024 to US$14.4 million in Q4 2025, and basic EPS has shifted from roughly US$0.35 to US$0.80. This sets up a story where higher net income and...
NasdaqGS:SGRY
NasdaqGS:SGRYHealthcare

Does Surgery Partners (SGRY) Guidance Cut Reveal a Deeper Shift in Case-Mix Strategy?

Recently, Surgery Partners reduced its earnings guidance after encountering slower surgical case growth, a less favorable payer mix, and reimbursement pressures across its facilities. An important angle is that the company is still prioritizing higher-acuity procedures and robotics investments, suggesting a focus on reshaping its case mix despite these operational challenges. We’ll now explore how this guidance cut, driven by slower case growth and payer mix headwinds, affects Surgery...
NasdaqGS:MEDP
NasdaqGS:MEDPLife Sciences

Medpace (MEDP) Margin Slippage Challenges Bullish Narratives Despite Solid Q4 EPS

Medpace Holdings (MEDP) has followed up its recent run of strong results with Q4 2025 revenue of US$708.5 million and basic EPS of US$4.78, backing that up with trailing 12 month revenue of about US$2.5 billion and EPS of US$15.64. Over recent quarters the company has seen revenue move from US$533.3 million in Q3 2024 to US$708.5 million in Q4 2025, while quarterly basic EPS has ranged from US$3.11 to US$4.78 across the same stretch. With trailing net profit margins at 17.8% versus 19.2% the...
NYSE:MSB
NYSE:MSBMetals and Mining

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...
NasdaqCM:FMAO
NasdaqCM:FMAOBanks

Farmers & Merchants Bancorp (FMAO) Net Interest Margin Improvement Tests Bullish Community Narratives

Farmers & Merchants Bancorp (FMAO) has put fresh numbers on the board, with Q4 2025 revenue of about US$31.9 million and basic EPS of US$0.70, supported by net income of US$9.7 million as the latest marker ahead of its Q1 2026 reporting period. The business has seen revenue move from US$26.6 million and EPS of US$0.59 in Q4 2024 to US$31.9 million and EPS of US$0.70 in Q4 2025. Trailing 12 month earnings growth of 29.4% and a 27.6% net margin frame a profitability profile that many investors...
NasdaqGM:SMBC
NasdaqGM:SMBCBanks

Southern Missouri Bancorp (SMBC) Net Interest Margin Holds At 3.57% Reinforcing Growth Narrative

Southern Missouri Bancorp (SMBC) opened Q3 2026 with Q2 results that put revenue and earnings in clear focus, reporting total revenue of US$48.0 million and basic EPS of US$1.62 on net income of US$18.1 million. The company has seen revenue move from US$41.7 million with EPS of US$1.10 in Q1 2025 to US$45.1 million and EPS of US$1.40 in Q4 2025, then to US$48.0 million and EPS of US$1.62 in Q2 2026. This latest report can be viewed as part of a steady earnings story that investors can now...
NasdaqGS:CARE
NasdaqGS:CAREBanks

Carter Bankshares (CARE) Net Interest Margin Improvement Tests Bearish Credit Risk Narratives

Carter Bankshares (CARE) opened Q1 2026 reporting Total Revenue of US$42.1 million in Q4 2025 and Basic EPS of US$0.38, with trailing twelve month EPS at US$1.38 and net income of US$31.0 million framing the latest run rate. Over the past year, Total Revenue on a trailing basis has moved from US$140.9 million to US$157.1 million while Basic EPS has shifted from US$1.06 to US$1.38, alongside earnings growth of 27.7% and net profit margin stepping up from 17.2% to 19.7%. For investors, these...
NasdaqGS:RBCA.A
NasdaqGS:RBCA.ABanks

Republic Bancorp (RBCA.A) Net Interest Margin Strength Reinforces Bullish Community Narratives

Republic Bancorp (RBCA.A) set the tone for Q1 2026 with recent results that sit against a trailing twelve month backdrop of US$385.9 million in revenue and basic EPS of US$6.65, underpinned by net income of US$131.3 million. Over the last few quarters, revenue has ranged from US$76.6 million to US$118.2 million per quarter while basic EPS moved between US$0.97 and US$2.40, giving investors a clear view of how the top and bottom lines have trended into the latest release. With a 34% net profit...
NYSE:OGS
NYSE:OGSGas Utilities

A Look At ONE Gas (OGS) Valuation As Recent Momentum Meets Tight Undervaluation Estimates

ONE Gas (OGS) has drawn fresh attention after its recent trading session, with the stock closing at $88.76. For investors, the move brings added focus to how the regulated utility’s fundamentals line up. See our latest analysis for ONE Gas. The latest move to $88.76 comes after a 14.93% 90 day share price return and a 16.97% total shareholder return over the past year, hinting that momentum has been building rather than fading. If this kind of steady utility performance has you thinking about...
NYSE:HZO
NYSE:HZOSpecialty Retail

MarineMax (HZO) Same Store Sales Growth Tests Bearish Profitability Narrative After Q1 Loss

MarineMax (HZO) has just posted its latest quarterly results, with Q1 2026 revenue of US$505.2 million and a basic EPS loss of US$0.36, alongside same store sales growth of 10.7%. The company has reported revenue of US$563.1 million in Q4 2024, US$631.5 million in Q2 2025, US$657.2 million in Q3 2025, US$552.2 million in Q4 2025, and US$505.2 million in Q1 2026, while EPS has ranged from a profit of US$0.80 in Q1 2025 to a loss of US$2.42 in Q3 2025. Margins remain under pressure, so this...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher Scientific (TMO) Margin Hold At 15% Tests Long Term Earnings Concerns

Thermo Fisher Scientific (TMO) has just put fresh numbers on the table, with Q4 2025 revenue of US$12.2b and basic EPS of US$5.22 setting the tone against a trailing twelve month EPS of US$17.78 on revenue of US$44.6b, alongside net income of US$6.7b. The company has seen quarterly revenue move from US$10.6b in Q3 2024 to US$12.2b in Q4 2025, while basic EPS over the same period went from US$4.27 to US$5.22. This gives investors a clear read on top line scale and earnings power as they assess...
NasdaqGS:KRNY
NasdaqGS:KRNYBanks

Kearny Financial (KRNY) Net Interest Margin Near 2.1% Challenges Bearish Narratives

Kearny Financial (KRNY) has just reported Q3 2026 results with quarterly revenue in the low US$40 million range and basic EPS of about US$0.15, set against a trailing twelve month EPS of US$0.52 that reflects the shift back into profitability. Over recent periods, revenue has moved from US$36.96 million in Q1 2025 to US$42.97 million in Q2 2026, while quarterly EPS has stepped from roughly US$0.10 to just over US$0.15. This gives investors a clearer read on how earnings now sit relative to...
NasdaqGS:FBNC
NasdaqGS:FBNCBanks

First Bancorp (FBNC) Q1 Net Income Rebound Tests Bearish Regional Bank Narratives

First Bancorp (FBNC) opened 2026 with Q1 results that put the focus squarely on the income statement, reporting total revenue of US$119.2 million and basic EPS of US$1.13, backed by trailing twelve month revenue of US$393.3 million and EPS of US$2.93. Over recent periods the company has seen quarterly revenue move from US$65.2 million in Q4 2024 to US$104.7 million in Q1 2025, US$108.8 million in Q2, US$86.2 million in Q3 and US$79.2 million in Q4, while EPS shifted from US$0.09 to US$0.88,...
NYSE:BMY
NYSE:BMYPharmaceuticals

Is It Too Late To Consider Bristol Myers Squibb (BMY) After A 27% One-Year Rally?

Investors may be wondering if Bristol-Myers Squibb at around US$59 a share still offers value, or if most of the opportunity is already priced in. The stock has returned 0.1% over the past week, 2.8% over the past month, 10.4% year to date and 27.3% over the last year, which naturally raises questions about what is currently baked into expectations. Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has centered on their pipelines, patent cycles and the role of...
NasdaqGS:MPWR
NasdaqGS:MPWRSemiconductor

A Look At Monolithic Power Systems (MPWR) Valuation As Investor Optimism Builds Before Upcoming Earnings

Why Monolithic Power Systems Stock Is Back in Focus Ahead of Earnings Investor attention around Monolithic Power Systems (MPWR) has picked up as the company approaches its next quarterly report, following upbeat Q4 2025 results and positive guidance for Q1 2026 revenue of US$770 million to US$790 million. See our latest analysis for Monolithic Power Systems. The recent enthusiasm around earnings has coincided with strong momentum, with a 30 day share price return of 44.53% and a 1 year total...